Perhaps a New Treatment Option for Patients with Intermediate Hepatocellular Carcinoma

Dr. Josep M. Llovet, Liver Cancer Program, Mount Sinai, New York, presents in this MEDtalk the results of the LEAP-012 phase II study of lenvatinib in combination with pembrolizumab plus transarterial chemoembolization for patients with intermediate hepatocellular carcinoma. The results show that the study hit the primary endpoint, progression-free survival for the combination arm. Regarding the other primary endpoint, overall survival, the analysis is still immature, but the study also showed a positive response.